Allup Silica Ltd

🇨🇦Canada

Country: 🇨🇦Canada

Ownership: -

Employees: 42

Market Cap: $7.1M

Website

Introduction: Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimen...

Clinical Trials

A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS

Phase 1

Active, not recruiting

Conditions: Myelodysplastic Syndromes
Acute Myeloid Leukemia

Interventions: Drug: CG-806

First Posted Date: 2020-07-20

Last Posted Date: 2023-12-15

Lead Sponsor: Aptose Biosciences Inc.

Target Recruit Count: 80

Registration Number: NCT04477291

Locations: 🇺🇸
University of Miami, Miami, Florida, United States
🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸
Ochsner Healthcare, New Orleans, Louisiana, United States

and more 7 locations

A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas

Phase 1

Active, not recruiting

Conditions: Chronic Lymphocytic Leukemia
Non-Hodgkin's Lymphoma
Small Lymphocytic Lymphoma

Interventions: Drug: CG-806

First Posted Date: 2019-03-28

Last Posted Date: 2023-12-15

Lead Sponsor: Aptose Biosciences Inc.

Target Recruit Count: 160

Registration Number: NCT03893682

Locations: 🇺🇸
University of California Los Angeles, Los Angeles, California, United States
🇺🇸
Fort Wayne Medical Oncology and Hematology, Fort Wayne, Indiana, United States
🇺🇸
University of Maryland, Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States

and more 27 locations

Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Phase 1

Recruiting

Conditions: Leukemia, Myeloid, Acute
Refractory AML
Relapsed Adult AML
Myelodysplastic Syndrome with Excess Blasts-2
Chronic Myelomonocytic Leukemia

Interventions: Drug: Tuspetinib
Drug: Venetoclax Oral Tablet
Drug: Azacitidine for Intravenous Infusion

First Posted Date: 2019-02-22

Last Posted Date: 2024-12-20

Lead Sponsor: Aptose Biosciences Inc.

Target Recruit Count: 240

Registration Number: NCT03850574

Locations: 🇺🇸
The Kirklin Clinic of UAB Hospital, Birmingham, Alabama, United States
🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸
University of California Irvine, Irvine, California, United States

and more 31 locations

A Study of APTO-253 in Patients With Relapsed or Refractory AML or MDS

Phase 1

Terminated

Conditions: Acute Myelogenous Leukemia, Adult
Acute Myelogenous Leukemia, Relapsed, Adult
Acute Myelogenous Leukemia in Relapse
High Risk Myelodysplasia
Acute Myelogenous Leukemia

Interventions: Drug: APTO-253

First Posted Date: 2014-10-20

Last Posted Date: 2022-08-22

Lead Sponsor: Aptose Biosciences Inc.

Target Recruit Count: 21

Registration Number: NCT02267863

Locations: 🇺🇸
UC San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸
University of Rochester; Wilmot Cancer Institute Clinical Trials Office, Rochester, New York, United States
🇺🇸
Ochsner Cancer Institute, New Orleans, Louisiana, United States

and more 10 locations

A Study of LOR-253 HCl in Patients With Advanced or Metastatic Solid Tumours

Phase 1

Completed

Conditions: Advanced or Metastatic Solid Tumours

Interventions: Drug: LOR-253 HCl

First Posted Date: 2011-01-24

Last Posted Date: 2014-02-25

Lead Sponsor: Aptose Biosciences Inc.

Target Recruit Count: 36

Registration Number: NCT01281592

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Combination of GTI-2040 and Cytarabine in the Treatment of Refractory and Relapsed Acute Myeloid Leukemia (AML)

Phase 2

Completed

Conditions: Acute Myeloid Leukemia

Interventions: Biological: GTI-2040

First Posted Date: 2007-11-29

Last Posted Date: 2015-07-27

Lead Sponsor: Aptose Biosciences Inc.

Target Recruit Count: 27

Registration Number: NCT00565058

Locations: 🇺🇸
UCSF Medical Center, San Francisco, California, United States
🇺🇸
The Ohio State University, Columbus, Ohio, United States
🇺🇸
San Francisco Veterans Affairs Medical Center, San Francisco, California, United States

and more 4 locations

Combination of Capecitabine and GTI-2040 in the Treatment of Renal Cell Carcinoma

Phase 1

Completed

Conditions: Carcinoma, Renal Cell
Metastases, Neoplasm

First Posted Date: 2003-03-10

Last Posted Date: 2008-01-07

Lead Sponsor: Aptose Biosciences Inc.

Target Recruit Count: 43

Registration Number: NCT00056173

Locations: 🇺🇸
Ochsner Clinic Foundation, New Orleans, Louisiana, United States
🇺🇸
Innovative Medical Research of South Florida, Inc., Miami Shores, Florida, United States
🇺🇸
CA Hematology Oncology Medical Group, Torrance, California, United States

and more 7 locations

A Study to Test the Effectiveness of Virulizin® Given in Combination With Standard Chemotherapy for Pancreatic Cancer

Phase 3

Completed

Conditions: Pancreatic Cancer

First Posted Date: 2002-06-20

Last Posted Date: 2008-01-07

Lead Sponsor: Aptose Biosciences Inc.

Target Recruit Count: 400

Registration Number: NCT00040092

Prev
1
Next

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy